Acute Intermittent Porphyria Clinical Trial
Official title:
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02922413 -
Panhematin for Prevention of Acute Attacks of Porphyria
|
Phase 2 | |
| Completed |
NCT02949830 -
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
|
Phase 1/Phase 2 | |
| Completed |
NCT02943213 -
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
|
Phase 1 | |
| Completed |
NCT02082860 -
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
|
Phase 1 | |
| Completed |
NCT02452372 -
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
|
Phase 1 | |
| Completed |
NCT00418795 -
Porphozym in the Treatment of Acute Attacks in AIP
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01617642 -
Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
|
||
| Completed |
NCT02076763 -
Observational Study of Acute Intermittent Porphyria Patients
|
N/A | |
| Active, not recruiting |
NCT02935400 -
Acute Porphyria Biomarkers for Disease Activity
|